Burning Mouth Syndrome (BMS): Treatments, Relief Strategies & Management

Understanding Burning Mouth Syndrome

Burning Mouth Syndrome (BMS) is a chronic, neuropathic pain condition characterized by a burning, scalding, or tingling sensation in the mouth (tongue, lips, palate, or diffuse) without visible mucosal lesions. It affects ~1–4% of adults, predominantly perimenopausal/postmenopausal women. Diagnosis is one of exclusion.

Multimodal Treatment Approach

No single cure exists; management combines pharmacologic, behavioral, and lifestyle interventions tailored to the individual.

Pharmacologic Options (Evidence-Based)

Class / Agent	Mechanism / Role	Typical Use	Key Considerations
Topical capsaicin (0.025–0.075% rinse/lozenge)	Depletes substance P from TRPV1 nociceptors	First-line topical; start low, titrate	Initial burning paradox; use after meals
Topical lidocaine (2% viscous, gel, spray)	Voltage-gated Na⁺ channel blockade	Prn for breakthrough pain	Limit frequency; avoid swallowing large amounts
Clonazepam (0.5 mg tablet sucked/swallowed)	GABA-A modulation; central & peripheral	Low dose HS or BID	Sedation, dependence risk; taper if stopping
Tricyclic antidepressants (amitriptyline 10–50 mg HS)	SNRI + Na⁺ channel blockade; central pain modulation	Neuropathic pain, comorbid insomnia	Anticholinergic SE; avoid in glaucoma, cardiac conduction disease
SSRIs/SNRIs (sertraline, duloxetine, venlafaxine)	Serotonin/norepinephrine reuptake inhibition	Comorbid anxiety/depression; neuropathic pain	4–8 weeks for full effect; activation syndrome initially
Gabapentin / Pregabalin	α2δ subunit of VGCC → reduce excitatory neurotransmission	Neuropathic component; allodynia	Renal dose adjust; dizziness, edema, weight gain
Alpha-lipoic acid (600 mg/day)	Antioxidant, mitochondrial support	Adjunct; some RCT support	Well-tolerated; monitor glucose if diabetic
Hormone therapy (HRT)	Estrogen replacement if perimenopausal	If BMS linked to estrogen decline	Individualize risks/benefits; not first-line for BMS alone

Non-Pharmacologic & Lifestyle Interventions

Saliva substitutes / sialogogues: Xylitol gum, pilocarpine, cevimeline for xerostomia component.
Dietary triggers to avoid: Spicy, acidic (citrus, tomato), very hot/cold, alcohol, caffeine, cinnamon, mint, SLS-containing toothpaste.
Oral hygiene: SLS-free toothpaste (e.g., Biotène, Sensodyne Pronamel), soft brush, alcohol-free mouthwash.
Stress reduction: CBT, mindfulness (MBSR), biofeedback, relaxation training—address central sensitization.
Acupuncture: Some RCTs show benefit; mechanism: endogenous opioid release, neuromodulation.
Cognitive-behavioral therapy (CBT): Reframes pain catastrophizing, improves coping.
Habit reversal: Tongue thrusting, clenching, lip biting.

Emerging / Refractory Options

Topical doxepin rinse (compounded)
Low-dose naltrexone (opioid receptor modulation)
Botulinum toxin injections (intralingual)
Transcranial magnetic stimulation (TMS)
Biologics (anti-CGRP, anti-IL-6): Case reports only; not standard.

Diagnostic Workup (Before Treatment)

Thorough history & oral exam (rule out candidiasis, lichen planus, geographic tongue, contact allergy, dental material sensitivity).
Labs: CBC, ferritin, B12, folate, zinc, TSH, fasting glucose/HbA1c, ESR/CRP, ANA, SPEP.
Salivary flow rate (sialometry).
Patch testing if contact allergy suspected.
Psychiatric screen (PHQ-9, GAD-7).

Follow-Up & Monitoring

Reassess at 4–6 weeks after intervention change.
Use validated scales: Visual Analog Scale (VAS), Oral Health Impact Profile (OHIP).
Adjust doses, rotate agents if inadequate response or side effects.
Multidisciplinary team: oral medicine, neurology, pain psychology, ENT, rheumatology as needed.

Prognosis: Variable. ~1/3 resolve spontaneously over years; ~1/3 improve with treatment; ~1/3 persist. Early multimodal intervention improves outcomes.